Johnson & Johnson Teclistamab Wins Second Indication in China for Post-Line Relapsed or Refractory Myeloma

Johnson & Johnson announced on October 22 that Talvey (teclistamab), a BCMA×CD3 bispecific antibody, has received an additional indication approval in China for adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. The drug was approved through priority review, marking its second approved indication in China and moving its treatment stage earlier, to first relapse.